Rep. April McClain Delaney Sells Bio-Techne Corp (NASDAQ:TECH) Shares

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of Bio-Techne Corp (NASDAQ:TECH). In a filing disclosed on March 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bio-Techne stock on February 24th.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of EMCOR Group (NYSE:EME) on 2/27/2026.
• Sold $1,001 – $15,000 in shares of Jones Lang LaSalle (NYSE:JLL) on 2/27/2026.
• Purchased $1,001 – $15,000 in shares of Nasdaq (NASDAQ:NDAQ) on 2/27/2026.
• Sold $1,001 – $15,000 in shares of Morningstar (NASDAQ:MORN) on 2/25/2026.
• Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Jones Lang LaSalle (NYSE:JLL) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of CDW (NASDAQ:CDW) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 2/23/2026.
• Purchased $15,001 – $50,000 in shares of Clean Harbors (NYSE:CLH) on 2/23/2026.

Bio-Techne Stock Performance

NASDAQ TECH traded down $1.14 during trading on Thursday, reaching $52.49. 556,998 shares of the company’s stock were exchanged, compared to its average volume of 2,443,344. The company has a debt-to-equity ratio of 0.13, a current ratio of 4.54 and a quick ratio of 3.08. The business has a 50 day moving average price of $62.56 and a 200-day moving average price of $59.99. The stock has a market capitalization of $8.21 billion, a P/E ratio of 102.98, a PEG ratio of 3.51 and a beta of 1.48. Bio-Techne Corp has a fifty-two week low of $46.01 and a fifty-two week high of $72.16.

Bio-Techne (NASDAQ:TECH) last issued its earnings results on Wednesday, February 4th. The biotechnology company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.43 by $0.03. The company had revenue of $295.88 million during the quarter, compared to the consensus estimate of $290.20 million. Bio-Techne had a return on equity of 13.94% and a net margin of 6.67%.The firm’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.42 EPS. Sell-side analysts forecast that Bio-Techne Corp will post 1.67 earnings per share for the current fiscal year.

Bio-Techne Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, February 27th. Shareholders of record on Monday, February 16th were given a dividend of $0.08 per share. This represents a $0.32 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Friday, February 13th. Bio-Techne’s payout ratio is 62.75%.

Analyst Upgrades and Downgrades

Several research firms have commented on TECH. Citigroup reiterated a “buy” rating and issued a $80.00 price objective (up from $70.00) on shares of Bio-Techne in a report on Wednesday, February 4th. Evercore upped their price target on shares of Bio-Techne from $62.00 to $68.00 and gave the company an “in-line” rating in a research note on Thursday, February 5th. TD Cowen reaffirmed a “buy” rating and set a $80.00 price target (up from $70.00) on shares of Bio-Techne in a research report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft set a $72.00 price objective on shares of Bio-Techne and gave the company a “buy” rating in a report on Friday, December 12th. Finally, Wells Fargo & Company increased their target price on shares of Bio-Techne from $70.00 to $76.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $72.77.

Institutional Investors Weigh In On Bio-Techne

Institutional investors and hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. lifted its holdings in shares of Bio-Techne by 12.0% in the first quarter. Goldman Sachs Group Inc. now owns 1,063,939 shares of the biotechnology company’s stock worth $62,379,000 after acquiring an additional 113,634 shares during the last quarter. Woodline Partners LP raised its holdings in Bio-Techne by 40.0% in the 1st quarter. Woodline Partners LP now owns 13,356 shares of the biotechnology company’s stock valued at $783,000 after buying an additional 3,814 shares during the last quarter. Assetmark Inc. boosted its position in Bio-Techne by 1,118.3% during the 2nd quarter. Assetmark Inc. now owns 1,401 shares of the biotechnology company’s stock worth $72,000 after buying an additional 1,286 shares during the period. Atria Investments Inc boosted its position in Bio-Techne by 31.1% during the 2nd quarter. Atria Investments Inc now owns 7,484 shares of the biotechnology company’s stock worth $385,000 after buying an additional 1,774 shares during the period. Finally, First Horizon Advisors Inc. grew its holdings in Bio-Techne by 134.6% during the 2nd quarter. First Horizon Advisors Inc. now owns 868 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 498 shares during the last quarter. Institutional investors own 98.95% of the company’s stock.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.